CN118121547A - Polypeptide guide molecule embedded lipid complex and preparation method and application thereof - Google Patents
Polypeptide guide molecule embedded lipid complex and preparation method and application thereof Download PDFInfo
- Publication number
- CN118121547A CN118121547A CN202410254290.6A CN202410254290A CN118121547A CN 118121547 A CN118121547 A CN 118121547A CN 202410254290 A CN202410254290 A CN 202410254290A CN 118121547 A CN118121547 A CN 118121547A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- lipid
- embedded
- itp
- targeting molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 151
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 121
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 113
- 150000002632 lipids Chemical class 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 238000010668 complexation reaction Methods 0.000 title description 2
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 15
- -1 lipid compound Chemical class 0.000 claims abstract description 10
- 239000002502 liposome Substances 0.000 claims description 101
- 230000008685 targeting Effects 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- 239000003960 organic solvent Substances 0.000 claims description 22
- 102000003746 Insulin Receptor Human genes 0.000 claims description 21
- 108010001127 Insulin Receptor Proteins 0.000 claims description 21
- 108010052285 Membrane Proteins Proteins 0.000 claims description 18
- 102000006495 integrins Human genes 0.000 claims description 18
- 108010044426 integrins Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 210000001808 exosome Anatomy 0.000 claims description 14
- 238000012377 drug delivery Methods 0.000 claims description 13
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 239000010408 film Substances 0.000 claims description 11
- 229940067606 lecithin Drugs 0.000 claims description 11
- 235000010445 lecithin Nutrition 0.000 claims description 11
- 239000000787 lecithin Substances 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 102000018697 Membrane Proteins Human genes 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 230000036571 hydration Effects 0.000 claims description 7
- 238000006703 hydration reaction Methods 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000009830 intercalation Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000005199 ultracentrifugation Methods 0.000 claims description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 108010068647 P2 peptide Proteins 0.000 claims description 3
- 101800004193 Peptide P3 Proteins 0.000 claims description 3
- 101800004196 Peptide P4 Proteins 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 1
- 229940089161 ginsenoside Drugs 0.000 claims 1
- 229930182494 ginsenoside Natural products 0.000 claims 1
- 230000004048 modification Effects 0.000 abstract description 26
- 238000012986 modification Methods 0.000 abstract description 26
- 239000012528 membrane Substances 0.000 abstract description 16
- 238000001727 in vivo Methods 0.000 abstract description 11
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003446 ligand Substances 0.000 abstract description 5
- 210000000170 cell membrane Anatomy 0.000 abstract description 4
- 230000002860 competitive effect Effects 0.000 abstract description 4
- 238000012217 deletion Methods 0.000 abstract description 2
- 230000037430 deletion Effects 0.000 abstract description 2
- 239000006274 endogenous ligand Substances 0.000 abstract description 2
- 230000035772 mutation Effects 0.000 abstract description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 18
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 239000004698 Polyethylene Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000011550 stock solution Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 238000004821 distillation Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000002189 fluorescence spectrum Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000004630 atomic force microscopy Methods 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 108700022423 fluorescein-isothiocyanated- insulin Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000010445 mica Substances 0.000 description 4
- 229910052618 mica group Inorganic materials 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 3
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- VBVAVBCYMYWNOU-UHFFFAOYSA-N coumarin 6 Chemical compound C1=CC=C2SC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 VBVAVBCYMYWNOU-UHFFFAOYSA-N 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- SBRPUFDSMGABKD-HZJYTTRNSA-N (6z,9z)-18-bromooctadeca-6,9-diene Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCBr SBRPUFDSMGABKD-HZJYTTRNSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000000198 fluorescence anisotropy Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 description 2
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 210000002487 multivesicular body Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical class C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229940040371 lecithin 10 mg Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medicines, and particularly relates to a polypeptide guide molecule embedded lipid compound and a preparation method and application thereof. The invention takes polypeptide ligand which can naturally embed into cell membrane and specifically recognize protein transmembrane region in the membrane as guide molecule, and the polypeptide can also be embedded into phospholipid bilayer to form lipid complex embedded with polypeptide guide molecule. The polypeptide guiding molecule embedded lipid complex can avoid the competitive recognition of endogenous ligand or antibody to target receptor, and can effectively avoid the target deletion caused by extracellular region mutation or shedding. The plug-and-play embedded modification mode can remarkably improve the immune compatibility of the lipid complex in vivo.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a polypeptide guide molecule embedded lipid complex taking a membrane protein transmembrane region as a target recognition site, and a preparation method and application thereof.
Background
The membrane proteins specific to the target cells provide important recognition sites for "targeting" the drug to the target tissue, and are an important biological basis for achieving targeted drug delivery. The polypeptide has natural high affinity and specificity to protein, and has the advantages of stronger permeability, lower potential immunogenicity and the like compared with macromolecules such as antibodies and the like. Thus, polypeptide ligands for specific target (membrane) proteins have become an important class of targeting molecules that mediate targeted drug delivery. The recognition of extracellular regions of target proteins exposed on the cell surface by polypeptide-like targeting molecules modified on the surface of the carrier is one of the important strategies for the current mode of targeted drug delivery. However, some disease-associated membrane proteins may have their extracellular regions shed under certain conditions (ectodomain shedding) resulting in "no target" and the shed extracellular regions may also become "pseudo targets". In vivo natural ligands or endogenous antibodies, which also have the extracellular region of the membrane protein as the binding region, may also cause competitive interference. Direct modification of liposomes with polyethylene glycol (PEG) can be problematic, where densely distributed polyethylene glycol on the surface of the liposome can cause significant steric hindrance to recognition of target proteins by polypeptide-directed molecules embedded in the phospholipid layer; repeated injections of polyethylene glycol liposomes have also been found in recent years to accelerate blood clearance (ACCELERATED BLOOD CLEARANCE, ABC) and to lose long circulation. At the same time, exogenous ligand molecules need to be exposed on the surface of the carrier to effectively recognize the extracellular region of the target receptor, but this modification is sterically hindered and shows varying degrees of immunogenicity. For example, RGD cyclic peptides are generally considered non-immunogenic, inducing an acute immune response in mice after conjugation with PEG on the surface of liposomes and multiple administrations, and even death (Wang X,Wang H,Jiang K,et al.Liposomes with cyclic RGD peptide motif triggers acute immune response in mice[J].Journal of Controlled Release,2019,293:201-214.); CDX peptides targeting nicotinic acetylcholine receptors (nicotinic acetylcholine receptors, nAChRs) on the blood brain barrier, when modified on liposomes, tend to adsorb native IgM, resulting in a more strongly immunogenic (Guan J,Shen Q,Zhang Z,et al.Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption[J].Nature communications,2018,9(1):2982.). modification of the polypeptide targeting molecule into the lipid complex phospholipid bilayer, can reduce steric hindrance and immunogenicity, but at the same time, whether the polypeptide sequence concealment resulting from the embedded modification affects its targeting function, and needs further experimental investigation.
Membrane proteins account for over 50% of the currently available drug targets, and research based on membrane proteins has focused mainly on extracellular and intracellular areas. With the development of structural biology, researchers have further developed into the transmembrane region of membrane proteins, which not only supports proteins across the cell membrane, but also plays an important role in the molecular and cellular recognition processes and is involved in protein-protein interactions. Interactions between transmembrane regions are associated with cell migration, proliferation, differentiation, and specific recognition of membrane proteins can be achieved by recognizing the transmembrane regions.
Therefore, the drug delivery system constructed in the form of the embedded polypeptide targeting molecule with the transmembrane region of the membrane protein as the target receptor recognition site is helpful to avoid various challenges caused by exposure of the polypeptide targeting molecule with the extracellular region of the membrane protein as the recognition site. The embedded modification mode can avoid the direct contact of the polypeptide and protease in vivo, and the constructed polypeptide guiding molecule embedded lipid complex can realize active targeting drug delivery perhaps through oral administration.
Disclosure of Invention
In view of the above, the present invention aims to provide a polypeptide targeting molecule embedded lipid complex using a membrane protein transmembrane region as a target recognition site, and a preparation method and application thereof.
In order to achieve the above purpose, the present invention provides the following technical solutions:
the invention provides a polypeptide targeting molecule embedded lipid complex, wherein the polypeptide targeting molecule can be embedded in a phospholipid bilayer of a lipid carrier and specifically identify a membrane protein transmembrane region, and the lipid complex is obtained by embedding a polypeptide targeting molecule into the lipid carrier.
The invention selects some polypeptide guide molecules taking membrane protein transmembrane regions as recognition sites for research, but is not limited to the polypeptides, including:
Polypeptide directed against the insulin receptor transmembrane region: ELGILIFLYLFSLILGIIYWKK (ITP peptide, 22 aa) as shown in SEQ ID NO. 1;
Polypeptide directed against the insulin receptor transmembrane region: LFGILIFLFLFSLIIGSIYLWKKK (P5 peptide, 24 aa) as shown in SEQ ID NO. 2;
Polypeptide directed against the integrin receptor transmembrane region: AYVFILLSFILGTLLGFLVMFWAKK (P4 peptide, 25 aa) as shown in SEQ ID NO. 3;
Polypeptide directed against the integrin receptor transmembrane region: AYVFILLSFILGTLLGFLVMFWA (P0 peptide, 23 aa) as shown in SEQ ID NO. 4;
Polypeptide directed against the integrin receptor transmembrane region: FILLSFILGTLLGFL (P1 peptide, 15 aa) as shown in SEQ ID NO. 5;
Polypeptide directed against the integrin receptor transmembrane region: FILLSFILGT (P2 peptide, 10 aa) as shown in SEQ ID NO. 6;
Polypeptide directed against the integrin receptor transmembrane region: PEEFILKSFILGTLKGFLKMFYS (P3 peptide, 23 aa) as shown in SEQ ID NO. 7;
polypeptide directed against the integrin receptor transmembrane region: DDEFILLSFILGTLKGFLKMFWS (AY peptide, 23 aa) as shown in SEQ ID NO. 8;
Polypeptide directed against the epidermal growth factor receptor-2 transmembrane region: TFIIATVEGVLLFLILVVVVGILIKRR (TF peptide, 27 aa) as shown in SEQ ID NO: 9.
The lipid carrier in the polypeptide targeting molecule embedded lipid complex with the membrane protein transmembrane region as a target point has a phospholipid bilayer, and mainly comprises the following three types, but is not limited to the three types, including:
Liposome: the liposome is a closed vesicle with a similar biological membrane structure and composed of phospholipid and the like, and the phospholipid layer is easy to modify hydrophobic polypeptide targeting molecules, has good cell affinity and tissue compatibility and is an ideal carrier;
exosomes: exosomes are multivesicular bodies derived from the invagination of intracellular lysosomal microparticles, which are fused with the cell membrane via the outer membrane of the multivesicular body and released into the extracellular matrix, comprising proteins, RNAs, DNA, lipids, metabolites and cytoplasmic molecules. Therefore, the exosomes have rich functions of achieving intercellular communication, transferring antigens to Dendritic Cells (DCs), promoting angiogenesis, achieving homing targets, and the like;
lipid nanoparticles: lipid nanoparticles are lipid vesicles with a homogeneous lipid core, widely used for delivery of small molecules and nucleic acid drugs. The lipid nanoparticle consists of ionizable cationic lipid (combined with nucleic acid electrostatically), neutral auxiliary phospholipid (accelerating the structural transformation of the lipid nanoparticle in cells to promote drug release), cholesterol (stabilizing the lipid nanoparticle structure), and PEG lipid (prolonging the plasma circulation time of the lipid nanoparticle).
In order to make the polypeptide targeting molecule embedded lipid complex of the invention have long circulation function, be better applied to in vivo drug delivery, the lipid complex can be modified by adopting gold standard 'PEG modification' with long circulation at present, and specifically DSPE-PEG 2000 is selected as a functional modification molecule.
The preparation method of the polypeptide guiding molecule embedded lipid compound comprises the step of preparing the polypeptide guiding molecule embedded lipid compound by adopting a film hydration method when the lipid carrier is lecithin. Such as: taking raw material polypeptide guide molecules and lecithin according to a mole ratio of 0.25-4%, precisely weighing, respectively dissolving raw materials by using an organic solvent, uniformly mixing, removing the organic solvent to form a lipid film, and drying the residual organic solvent. Immediately adding PBS buffer solution, oscillating until lipid membrane is fully dissolved and dispersed, controlling particle size by ultrasonic and pushing, and filtering to obtain the final product.
When the lipid carrier is exosome, the preparation method is as follows:
The RAW 264.7 cell supernatant was collected and centrifuged to remove cells and other debris. The obtained supernatant was centrifuged at 135,000g for 1h, and the precipitate was washed with PBS to obtain exosomes. The polypeptide targeting molecule is dissolved in an organic solvent and incubated with the exosomes. Unbound polypeptide-directed molecules are removed by ultracentrifugation.
When the lipid carrier is a lipid nanoparticle, the preparation method is as follows: the ionizable lipid ingredient, DSPC, steroid, DMG-PEG 2000, and polypeptide targeting molecule were dissolved in an organic solvent and mixed in a molar ratio (50:10:34.5:1.5:4), respectively. The aqueous phase and the organic solution were mixed at a volume ratio of 3:1 with DEPC water as the aqueous phase at a mixing rate of 12 mL/min. Dialyzing overnight with dialysis bag with molecular weight of 8-14K. The ionizable lipid ingredient is Dlin-MC3-DMA or A1 (2- (di ((9E, 12E) -octadeca-9, 12-dien-1-yl) amino) ethyl (4 1 R,13 aS) -13 a-ethyl-2, 3,4 1, 5,6,13 a-hexahydro-1H-indolo [3,2,1-de ] pyrido [3,2,1-ij ] [1,5] naphthyridine-12-carboxylate); the steroid compound is cholesterol (Chol) or ginsenoside Rg5. Wherein A1 is a vincamine derivative, and has the structural formula:
the polypeptide targeting molecule embedded lipid complex of the invention can be applied as a targeted drug delivery system. Such as brain-targeted drug delivery systems and tumor-targeted drug delivery systems.
The invention has the beneficial effects that:
(1) The invention takes polypeptide ligand which can naturally embed into cell membrane and specifically recognize protein transmembrane region in the membrane as guide molecule, and the polypeptide can also be embedded into phospholipid bilayer of lipid complex to form lipid complex with embedded polypeptide guide molecule. The polypeptide targeting molecule embedded lipid complex can avoid the competitive recognition of the target receptor by endogenous ligands or antibodies;
(2) Different from many drug delivery researches taking extracellular regions of membrane proteins as recognition sites, the polypeptide embedded lipid complex provided by the invention recognizes more conserved and stable transmembrane regions of membrane proteins, can effectively avoid target deletion caused by extracellular region mutation or shedding, and can also effectively prevent competitive interference of natural ligands or endogenous antibodies in vivo.
(3) The lipid complex embedded in the polypeptide targeting molecule does not need to expose the targeting molecule, the in vivo stability of some polypeptides with a plurality of enzyme cutting sites is obviously improved, the coupling of the carrier and the polypeptide by a chemical method is avoided, the preparation is easy, the preparation can be used in a plug-and-play way, and the constructed preparation has low immunogenicity and good stability.
(4) The polypeptide guiding molecule embedded lipid complex has universality and can be expanded to other targeted drug delivery mediated by a transmembrane receptor.
Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the invention. The objects and other advantages of the invention may be realized and obtained by means of the instrumentalities and combinations particularly pointed out in the specification.
Drawings
For the purpose of making the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in the following preferred detail with reference to the accompanying drawings, in which:
FIG. 1 is an analysis of the response of ITP peptides (A) and SP (B) to IR recombinant liposome interactions in example 1;
FIG. 2 is a graph showing insulin competition binding to primary brain endothelial cell uptake results in example 2;
FIG. 3 shows the anisotropy values of NBD-PE probes at 30, 35, 40℃for different liposomes in example 3, respectively;
FIG. 4 is Young's modulus values for Lip and ITP-Lip in example 3;
FIG. 5 shows uptake results of various proportions of ITP peptide modified liposomes by bEnd.3 cells in example 4;
FIG. 6 shows the uptake results of bEnd.3 cells of example 5 on different ratios of DSPE-PEG 2000 modified ITP-Lip;
FIG. 7 is a morphology of the polypeptide targeting molecule embedded lipid complex of example 6;
FIG. 8 is a fluorescence spectrum of Lip, ITP and ITP-Lip at a wavelength of 400-305 nm in example 7;
FIG. 9 is a fluorescence spectrum of Lip, AY and AY-Lip at a wavelength of 400 to 305nm in example 7;
FIG. 10 is a FRET fluorescence spectrum and corresponding quantitative result of FRET efficiency for DiI and DiD liposomes entrapped in example 8;
FIG. 11 shows the change in FRET efficiency in serum for different liposomes in example 8;
FIG. 12 shows the results of cellular uptake of liposomes modified with different polypeptides of example 9;
FIG. 13 is a photograph of a living small animal in example 9;
FIG. 14 is an SDS-PAGE protein adsorption analysis in example 10;
FIG. 15 shows the FRET imaging results of ITP peptide-intercalating modified liposomes in small intestine sections of example 11.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention. It should be noted that the illustrations provided in the following embodiments merely illustrate the basic idea of the present invention by way of illustration, and the following embodiments and features in the embodiments may be combined with each other without conflict.
1. Experimental cell strain
Mouse brain microvascular endothelial cells (bend.3), mouse mononuclear macrophages (RAW 264.7) were purchased from marsupenario life technologies limited.
The primary brain endothelial cells (BMECs) were extracted according to the following experimental procedure:
(1) Female SD rats of 4-6 weeks old were sacrificed with excess anesthesia, sterilized by 75% ethanol twice (1 st quick wash, 2 nd appropriate soak, no more than 5 min), the scalp and skull of the rats were sequentially sheared off under aseptic conditions, the brains carefully removed, and placed in petri dishes containing cold D-Hanks solution (tissue isolation was performed entirely on ice). Carefully removing meninges and large blood vessels by using sterilizing filter paper, removing olfactory bulb, thalamus, midbrain, cerebellum, pontine and the like, leaving only cerebral cortex layer, and carefully removing large blood vessels;
(2) The cortical layer was sheared, centrifuged (1200 rpm,5 min) in a sterile 15mL centrifuge tube, 25% BSA (W: V) solution was added to the pellet layer at a 1.5:1 (V: V) ratio, and repeatedly blown with a pipette to form a cortical homogenate, which was then centrifuged at 2500rpm for 5min, and the pellet vessel segments were collected. Collecting supernatant, repeatedly blowing with a pipettor, centrifuging at 2500rpm for 5min, collecting the precipitated vessel segment again, and combining the vessel lengths collected twice to extract the microvasculature to the maximum extent;
(3) The vessel sections obtained by the two centrifugation were rinsed with cold D' Hanks solution and centrifuged (2500 rpm,5 min), 0.1% type II collagenase (W: V) was added at 1:5 (V: V), and digested at 37℃for 5min. Taking out the sample after digestion, adding a complete culture medium containing 20% of serum, blowing for about 10 times by using a pipette, and centrifuging for 5min under the condition of 1200rpm to obtain the cerebral cortex microvascular endothelial cells containing the microvascular segments. Cells were suspended in a complete medium containing 20% FBS, and the cell suspension was inoculated into a flask, and after culturing in a 5% CO 2 incubator at 37℃for 24 hours, the flask was changed (the flask was shaken thoroughly to detach the attached tissue mass). When the confluency of the cultured cells reaches 80%, the cultured cells can be subjected to passage purification and then used for experiments.
Unless otherwise specified, the culture media used in the experiments of bEnd.3 and BMECs in the examples were DMEM complete medium containing 10% Fetal Bovine Serum (FBS) and 1% penicillin and streptomycin mixed solution (P/S).
2. Experimental animal
Balb/c mice, females, 6-8 weeks old, SD rats, females, 4-6 weeks old, provided by Chongqing Chinese traditional medicine institute laboratory animal research institute. Animals were kept in SPF-class animal houses and the animals were fasted for 24 hours prior to the experiment without water deprivation. The experimental study is strictly carried out according to the guidance opinion on animals to be tested of the Chinese scientific technical section.
The construction method of the mouse breast cancer TUBO subcutaneous tumor model comprises the following steps:
after digestion of 5×10 6 mouse breast cancer TUBO cells, the cells were washed 2 times with PBS, and after centrifugation to collect cell pellet, resuspended in 200 μl PBS. 100. Mu.L of the cell suspension was aspirated using a 500. Mu.L syringe and subcutaneously injected into the Balb/c mouse forelimb armpit. The TUBO breast cancer tumor-bearing mouse model is normally fed in an SPF-level feeding environment, the tumor growth state is detected on time, and the model can be used for subsequent experiments when the subcutaneous tumor volume is about 150mm 3.
3. Experimental materials
The specific preparation of compound A1 (2- (di ((9E, 12E) -octadeca-9, 12-dien-1-yl) amino) ethyl (4 1 R,13 aS) -13 a-ethyl-2, 3,4 1, 5,6,13 a-hexahydro-1H-indolo [3,2,1-de ] pyrido [3,2,1-ij ] [1,5] naphthyridine-12-carboxylate) is shown below:
(1) (6Z, 9Z) -18-bromooctadecane-6, 9-diene (C5-Br) (400 mg, 1.21 mmol), 2-aminoethanol (HO-B1-NH 2) (35. Mu.L, 0.552 mmol), potassium carbonate (330 mg, 2.43 mmol) and potassium iodide (9 mg, 0.552 mmol) were dissolved in 5mL of acetonitrile in a molar ratio of 1.21:0.552:2.43:0.552, and the reaction mixture was heated and stirred at 65℃for 24h;
(2) Cooling to room temperature, washing the filter cake obtained by filtration with n-hexane for 3 times, extracting the filtrate obtained by filtration with n-hexane, concentrating under reduced pressure, separating by silica gel chromatography (methanol/dichloromethane=15/85 (v/v)), and obtaining an intermediate compound by rotary evaporation;
(3) A1-OH (50 mg, 0.15 mmol), intermediate compound (88 mg,1.59 mmol), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC. HCl,35mg, 0.183 mmol) and 4-dimethylaminopyridine (DMAP, 1mg,0.0081 mmol) were dissolved in 6mL pyridine/dichloromethane (1/1, v/v) and the reaction mixture was stirred at room temperature for 24h;
(4) The organic phase obtained by the separation was diluted with dichloromethane (6 mL), washed 4 times with 5mL of a 2M hydrochloric acid solution, saturated brine each, then dried over sodium sulfate, concentrated under reduced pressure, and separated by silica gel chromatography (acetone/n-hexane=1/1 (v/v); dichloromethane/methanol=1/3 (v/v)), and the final product was obtained as a vincamine derivative A1 by rotary evaporation 1H NMR(400MHz,DMSO-d6)δ7.43(dd,J＝6.7,2.7Hz,1H),7.05(d,J＝6.9Hz,3H),5.32(pd,J＝11.0,4.5Hz,10H),2.74(t,J＝6.3Hz,4H),2.18(s,4H),2.02(q,J＝6.8Hz,9H),1.78(tq,J＝7.0,3.6Hz,4H),1.35-1.22(m,44H),1.05(t,J＝7.1Hz,3H),0.87(q,J＝7.0,5.6Hz,9H)..
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications. In the following examples, the operating temperature and pressure are generally room temperature and normal pressure unless otherwise specified. Wherein, the room temperature is 10-30 ℃; atmospheric pressure refers to a standard atmospheric pressure.
EXAMPLE 1SPR analysis of ITP peptide affinity with Insulin Receptor (IR) recombinant liposomes
10Mg of lecithin (EPC) is taken, precisely weighed, dissolved in a methanol-chloroform (1:1, V:V) mixed solution, transferred into a round bottom distillation flask, the organic solvent is removed by adopting a rotary evaporator, and after lipid films are formed at the bottom of the flask, nitrogen is introduced to blow dry the residual organic solvent. Immediately adding 1mL of IR recombinant protein into a round bottom flask, putting into a constant temperature oscillator for shaking until lipid membranes are fully dissolved and dispersed, and finally putting into an ultrasonic cell disruption instrument for ultrasonic preparation of liposome, wherein the ultrasonic treatment is carried out for 10 times, 5 s/time and 5s at intervals. Repeatedly squeezing with liposome extruder to control particle diameter, and sequentially passing through polycarbonate filter membranes of 400, 200 and 100nm to obtain IR recombinant liposome.
The SPR instrument was ligated and calibrated, the surface of an L1 chip (model SLD0930; nicoya, KITCHENER, ON, canada) was initialized by injecting 200. Mu.L of 20mM CHAPS buffer, the sample loop was washed with PBS buffer and emptied with air 3 times, the prepared IR recombinant liposomes were immobilized ON the L1 chip, and after each injection of solutions of ITP peptides (amino acid sequence ELGILIFLYLFSLILGIIYWKK) at different concentrations (125, 250, 500, 1000 and 2000nM, respectively) and the affinity of the polypeptides to the IR recombinant liposomes was evaluated by fitting the resulting data with out-of-order peptides (Scrambled peptide, SP, amino acid sequence WEILGIGLFLYILSIFILLIKK, available from Shanghai Fin Biotechnology Co., ltd.) as control polypeptide solutions at concentrations of 125, 250, 500, 1000 and 2000nM, respectively.
From FIGS. 1A and 1B, it can be seen that at the same polypeptide concentration, the response of ITP peptide to IR recombinant liposome action was significantly higher than that of the disordered peptide SP. The fit of the ITP to the IR recombinant liposome effect was 2.10x -7 M, significantly lower than the fit between SP and IR recombinant liposome results, with smaller KD values indicating greater affinity effects between the test samples.
Example 2 verification of ITP peptide specific binding to IR transmembrane region
Primary brain endothelial cells (BMECs) were pre-seeded in 12-well plates (2X 10 5 per well) and incubated at 37℃for 24 hours. The medium was discarded, replaced with fresh medium containing 1.25. Mu.M insulin or ITP peptide at concentrations of 1.25, 2.5, 5 and 10. Mu.M, and incubated for 1 hour at 37 ℃. The medium was discarded, fresh medium was added, 20. Mu.g/mL FITC-insulin was added to the corresponding 12-well plate, and incubated at 37℃for 1 hour. Cells were then collected, washed three times with PBS and the uptake of FITC-insulin by the cells was determined using a flow cytometer.
Following insulin pre-incubation, BMECs uptake of FITC-insulin was inhibited due to competitive binding of previously pre-incubated insulin to the extracellular region of IR. Whereas preincubation with ITP peptide did not interfere with BMECs uptake of FITC-insulin (fig. 2), indicating that ITP specifically binds to the IR transmembrane region.
Example 3 Effect of ITP peptide modification on phospholipid Membrane fluidity and Liposome elastic modulus
The membrane hydration method is adopted to prepare NBD-PE fluorescence labeling liposome, and the change of the membrane fluidity is evaluated by measuring the fluorescence anisotropy of a fluorescence probe NBD-PE in the liposome.
Preparation of blank liposomes:
similar to the preparation method of the IR recombinant liposome, the difference is that: 1mL of IR recombinant protein was replaced with 1mL of PBS buffer.
Preparation of NBD-PE fluorescence labeled liposome:
Firstly, a proper amount of NBD-PE is taken, precisely weighed, dissolved in a small amount of chloroform and diluted with methanol to a final concentration of 1mg/mL of stock solution. According to cholesterol: EPC or ITP: the EPC (0.25%, 0.5%,1%,2%,4%, mole ratio) is prepared by taking cholesterol and ITP polypeptide, precisely weighing, respectively dissolving with a methanol-chloroform (1:1, V: V) mixed solution and ethanol in proper amounts, respectively mixing with lecithin uniformly, and according to NBD-PE: lecithin (1:200, molar ratio) was added to the corresponding volume of NBD-PE stock solution. And (3) uniformly mixing, transferring to a round bottom distillation flask, removing the organic solvent by adopting a rotary evaporator, and obtaining the NBD-PE fluorescence-labeled cholesterol liposome (CHL-Lip) and the NBD-PE fluorescence-labeled ITP-modified liposome (ITP-Lip) respectively in the subsequent steps consistent with the preparation method of the blank liposome.
And (3) measuring the anisotropic change of the NBD-PE fluorescent probes in different liposomes under different temperature conditions (30, 35 and 40 ℃) by using a multifunctional enzyme-labeled instrument. The fluorescence anisotropy (r) is calculated as follows: r= (I/-I Γ)/(I/+2i), where I/, and I Γ are the fluorescence intensities measured on the polarization plane of the emitted light, parallel and perpendicular to the polarized excitation beam, respectively. The excitation and emission wavelengths of NPD-PE were 463nm and 534nm, respectively.
Changes in Young's Modulus (Young's Modulus) of the preparation after ITP modification of the liposomes were measured by Atomic Force Microscopy (AFM), and the effect of ITP modification on the elastic Modulus of the liposomes was evaluated. And (3) taking mica sheets matched with the AFM, and coating the mica sheets with polylysine solution in advance. Diluting the prepared liposome sample with ultrapure water until the final concentration of phospholipid is 2mg/mL, taking 10 mu L of diluted sample, carefully dripping the diluted sample onto the mica sheet, and standing for 10min to enable the liposome to be adsorbed on the mica sheet. And then blowing off the unadsorbed sample with nitrogen at a low speed, and obtaining the sample, wherein the sample is successfully prepared, and the Young modulus of the sample is analyzed by AFM measurement.
The effect of ITP modification on liposome membrane fluidity was evaluated using cholesterol modification as a control. As shown in fig. 3, ITP was significantly better than cholesterol in reducing membrane fluidity at the same molar ratio of cholesterol or ITP modification, and there was a significant difference and positive correlation with ITP concentration change. When the temperature was lowered, both cholesterol and ITP modifications, the fluorescence probe NBD-PE anisotropy increased to some extent, indicating a decrease in liposome membrane fluidity. In conclusion, ITP modifications have better stabilizing effects on liposomes than cholesterol.
As can be seen from fig. 4, the young modulus of the ITP-Lip is about 35.19 times that of the unmodified liposome Lip, which indicates that the ITP modification can significantly improve the rigidity of the liposome, and has good supporting effect on the liposome structure, so that the liposome is stabilized, and the probability of drug leakage can be reduced.
Example 4 Effect of ITP peptide modification ratio on uptake of liposomes by cells
Coumarin 6 (C6) fluorescein-labeled ITP-Lip is prepared by a film hydration method. The method comprises the following specific steps: and (3) taking a proper amount of C6 fluorescein, precisely weighing, and dissolving in a methanol-chloroform (1:1, V:V) mixed solution until the final concentration of the fluorescein is 1mg/mL to obtain a C6 fluorescein stock solution. Lecithin 10mg was taken, precisely weighed, and dissolved in a methanol-chloroform (1:1, V: V) mixed solution. According to ITP: the ITP polypeptide and EPC are taken according to the proportion of 0.25%,0.5%,1%,2%,4% and mole ratio, and the ITP polypeptide is dissolved in proper amount of ethanol. And mixing lecithin solution and ITP polypeptide solution, adding appropriate amount of C6 stock solution to make the final concentration of the stock solution in liposome solution be 10 mug/mL, transferring to a round bottom distillation flask, removing organic solvent by adopting a rotary evaporator in the dark, forming a lipid film at the bottom of the flask, and blowing nitrogen into the flask to dry the residual organic solvent. Immediately adding 1mL of PBS buffer solution into a round-bottom flask, putting into a constant-temperature oscillator for oscillation until the lipid membrane is fully dissolved and dispersed, and carrying out subsequent steps in the same way as the preparation of blank liposome in the embodiment 3 to obtain the C6 fluorescein labeled liposome modified by different ITP proportions.
The bEnd.3 cells in the logarithmic growth phase were digested and counted using a hemocytometer, seeded into 12-well plates at an seeding concentration of 2X 10 5 cells/well, and placed in a cell incubator for 24h (37 ℃,5% CO 2). The medium in the wells is discarded, the fresh complete medium is replaced, the prepared liposomes modified by different ITP ratios of the C6 markers are added to a final concentration of 1 mug/mL, and the liposomes are placed in an incubator and incubated in a dark place for ingestion for 2 hours. After the end of the uptake, the liposome-containing medium was aspirated, the cells were digested with trypsin for about 3min, pancreatin was discarded and washed three times with PBS, the cells were resuspended with PBS, centrifuged at 1000g for 5min, the supernatant was discarded and the pelleted cells were collected, 500. Mu.L of resuspended cells were added, and the cell uptake fluorescence intensity was measured using a flow cytometer.
As shown in fig. 5, the fluorescence intensity of 2% ITP-modified liposomes was about 1.21 times that of the control group, and the fluorescence intensity of 4% ITP-modified liposomes was about 1.72 times that of the control group, each of which was significantly different. Considering the complexity of the subsequent in vivo environment, the proportion of ITP modified liposomes was chosen to be 4% in order to reduce the influence of factors such as non-target sites and endogenous substances as much as possible.
Example 5 Effect of DSPE-PEG 2000 modification ratio on uptake of liposomes by cells
In order to enable the ITP-Lip to have a long circulation function, the ITP-Lip is better applied to in vivo drug delivery, the ITP-Lip is modified by adopting gold standard 'PEG modification' of the current long circulation, and DSPE-PEG 2000 is specifically selected as a functional modification molecule. According to EPC: ITP: DSPE-PEG 2000 (100:4:5/100:4:10/100:4:15/100:4:20, molar ratio) was taken in proportion EPC, ITP, DSPE-PEG 2000, precisely weighed. Except for the ITP, the materials were dissolved in ethanol with a methanol-chloroform (1:1, V: V) mixture. The EPC, ITP and DSPE-PEG 2000 solutions corresponding to each formulation were mixed uniformly, transferred to a round bottom distillation flask, the organic solvent was removed using a rotary evaporator, and the subsequent steps were examined with reference to the "blank liposome preparation" in example 3 and the flow detection method in example 4.
The quantitative analysis results of flow cytometry are shown in fig. 6, in which the 5% PEG-ITP-Lip group showed a decrease in uptake compared to the ITP-Lip group, but there was still a significant difference (P < 0.001) from the Lip group. In view of the long circulation and active targeting of the balanced formulation, 5% DSPE-PEG 2000 was used to modify ITP-Lip to prepare PEG-ITP-Lip.
EXAMPLE 6 particle size and morphology characterization of polypeptide-directed molecular intercalating lipid complexes
The liposome is prepared by adopting a film hydration method. Precisely weighing nine polypeptides according to the optimal molar ratio of the screened polypeptides to DSPE-PEG 2000 (EPC: polypeptide: DSPE-PEG 2000 =100:4:5), wherein the nine polypeptides comprise:
polypeptide directed against the insulin receptor transmembrane region: ELGILIFLYLFSLILGIIYWKK (ITP peptide, 22 aa);
Polypeptide directed against the insulin receptor transmembrane region: LFGILIFLFLFSLIIGSIYLWKKK (P5 peptide, 24 aa);
polypeptide directed against the integrin receptor transmembrane region: AYVFILLSFILGTLLGFLVMFWAKK (P4 peptide, 25 aa);
Polypeptide directed against the integrin receptor transmembrane region: AYVFILLSFILGTLLGFLVMFWA (P0 peptide, 23 aa);
Polypeptide directed against the integrin receptor transmembrane region: FILLSFILGTLLGFL (P1 peptide, 15 aa);
polypeptide directed against the integrin receptor transmembrane region: FILLSFILGT (P2 peptide, 10 aa);
polypeptide directed against the integrin receptor transmembrane region: PEEFILKSFILGTLKGFLKMFYS (P3 peptide, 23 aa);
Polypeptide directed against the integrin receptor transmembrane region: DDEFILLSFILGTLKGFLKMFWS (AY peptide, 23 aa);
Polypeptide directed against the epidermal growth factor receptor-2 transmembrane region: TFIIATVEGVLLFLILVVVVGILIKRR (TF peptide, 27 aa).
Except for ITP and P5, the polypeptides and materials were dissolved in a methanol-chloroform (1:1, V: V) mixture. And (3) uniformly mixing the polypeptide solution, the EPC solution and the DSPE-PEG 2000 solution, transferring to a round bottom distillation flask, removing the organic solvent by adopting a rotary evaporator, and performing the subsequent steps on the polypeptide solution, the EPC solution and the DSPE-PEG 2000 solution to obtain the polypeptide-targeted molecule embedded liposome. The particle size distribution of each liposome prepared was measured using a malvern laser particle sizer.
The RAW 264.7 cell-derived exosomes were isolated by ultracentrifugation and exosomes embedded in ITP polypeptides (ITP-exosomes) were prepared. RAW 264.7 cell supernatants were collected and centrifuged at 5,000g for 30min,10,000g for 1h to remove cells and other debris. The obtained supernatant was centrifuged at 135,000g for 1h, and the precipitate was washed with PBS to obtain exosomes. ITP was dissolved in absolute ethanol and incubated with exosomes for 30min at 37 ℃. Unbound ITP was removed by ultracentrifugation at 135,000g for 1h and the pellet was the ITP-Exosome.
ITP polypeptide embedded lipid nanoparticles (PEG-ITP-LNP) were prepared using a microfluidic device (model: MPE, ai Tesen pharmaceutical Equipment Co., ltd.). Dlin-MC3-DMA, DSPC, chol, DMG-PEG 2000 and ITP were dissolved in ethanol and mixed in the appropriate molar ratio (50:10:34.5:1.5:4), respectively. The DEPC water is taken as an aqueous phase, and the aqueous phase and the ethanol solution are mixed according to the volume ratio of 3:1 at the mixing rate of 12 mL/min. Dialyzing overnight with dialysis bag with molecular weight of 8-14K to obtain PEG-ITP-LNP.
ITP polypeptide embedded ionizable lipid nanoparticles (PEG-ITP-VIP, PEG-ITP-Rg 5-VIP) were prepared using a microfluidic device (model: MPE, ai Tesen pharmaceutical Equipment Co., st.). The ionizable lipid fraction in the PEG-ITP-LNP preparation step was replaced by Dlin-MC3-DMA with A1 (2- (di ((9E, 12E) -octadeca-9, 12-dien-1-yl) amino) ethyl (4 1 R,13 aS) -13 a-ethyl-2, 3,4 1, 5,6,13 a-hexahydro-1H-indolo [3,2,1-de ] pyrido [3,2,1-ij ] [1,5] naphthyridine-12-carboxylate) and the other materials were unchanged, and PEG-ITP-VIP was obtained according to the preparation method described above. The PEG-ITP-Rg5-VIP is prepared by substituting ionizable lipid component Dlin-MC3-DMA with A1, substituting Chol with ginsenoside Rg5 (Xiamen Bensu pharmaceutical Co., ltd.) and other materials.
The particle size and morphology of each lipid complex prepared were characterized using a malvern laser particle sizer and a transmission electron microscope.
TABLE 1 particle size of polypeptide targeting molecule Embedded lipid complexes
| Formulations | Particle size (nm) | PDI |
| PEG-ITP-Lip | 87.40±9.81 | 0.146±0.049 |
| ITP-Exosome | 174.20±5.54 | 0.112±0.005 |
| PEG-ITP-LNP | 123.39±3.12 | 0.224±0.015 |
| PEG-ITP-VIP | 86.60±1.21 | 0.117±0.013 |
| PEG-ITP-Rg5-VIP | 89.95±2.32 | 0.132±0.009 |
| PEG-P5-Lip | 85.88±5.54 | 0.157±0.021 |
| PEG-P1-Lip | 76.33±8.92 | 0.208±0.022 |
| PEG-P2-Lip | 75.89±6.77 | 0.116±0.009 |
| PEG-P3-Lip | 98.08±6.18 | 0.165±0.032 |
| PEG-P4-Lip | 95.37±8.04 | 0.187±0.025 |
| PEG-P0-Lip | 92.90±6.22 | 0.110±0.008 |
| PEG-AY-Lip | 85.12±3.98 | 0.106±0.058 |
| PEG-TF-Lip | 75.44±5.12 | 0.219±0.011 |
The results are shown in Table 1 and FIG. 7, in which the PDI value of the polypeptide targeting molecule-embedded lipid complex is small, and the particle size is uniform and the morphology is round.
EXAMPLE 7 fluorescence Spectroscopy characterization of ITP and AY peptide-embedded liposomes
Fluorescence intensity was measured on an F-7000 fluorescence spectrometer using a cuvette of 0.1cm path length. Unmodified blank liposomes (Lip) were prepared as in example 3; ITP and AY peptide-embedded liposomes (ITP-Lip, AY-Lip) were prepared by thin film hydration (EPC, ITP, AY was taken at 4% (molar ratio) of ITP/AY: EPC; except for the dissolution of ITP with ethanol, the remaining materials were dissolved with a methanol-chloroform (1:1, V: V) mixture, the EPC, ITP or AY solutions corresponding to each formulation were transferred to a round bottom distillation flask, the organic solvent was removed by rotary evaporator, and ITP, AY, lip, ITP-Lip and AY-Lip were diluted to 1mg/mL with 2, 2-trifluoroethanol for the subsequent steps with reference to "blank liposome preparation" in example 3. The excitation and emission slit widths were set to 2.5nm and 1.5nm, respectively, with an average time of 1.0 seconds. 280nm excitation is set, and emission scanning is carried out on the wavelength of 400-305 nm.
As shown in figures 8 and 9, at the wavelength of 400-305 nm, the Lip has no obvious fluorescence signal, and the maximum absorption wavelength of the fluorescence spectrum of the ITP-Lip and the AY-Lip has obvious blue shift compared with the free ITP and AY, and the fluorescence signal intensity is increased, thus proving that the polypeptide molecules are successfully embedded into the liposome phospholipid bilayer.
EXAMPLE 8 stability investigation of ITP peptide-embedded modified liposomes
The serum stability of the formulations was characterized using Fluorescence Resonance Energy Transfer (FRET) experiments, with fluorescein DiI as the fluorescent pair and di as the donor molecule (ex=549 nm, em=565 nm) and di as the acceptor molecule (ex=644 nm, em=663 nm). Proper amounts of fluorescein DiI and DiD are taken, precisely weighed, dissolved in ethanol and diluted to a final concentration of 1 mug/mL of stock solution for later use. Fluorescein DiI and DiD double-fluorescence labeled Lip were prepared according to the preparation method of coumarin 6 fluorescence labeled liposomes in example 4, wherein final concentration of fluorescein DiI in the prepared liposomes was 10 μg/mL, diD fluorescein was entrapped according to DiI: diD (1:1/1:2/1:3, mass ratio) to screen for preferred FRET fluorescence pair combinations. Separately, liposomes were prepared with fluorescein DiI and DiD, respectively, and two single fluorescently labeled liposomes were physically mixed as a control group. Scanning FRET fluorescence spectrum by using a multifunctional enzyme-labeled instrument, and calculating FRET efficiency, wherein the calculation formula is as follows: fretratio= IDiD/(IDiD + IDiI), where IDiD and IDiI are fluorescence intensity values at 663nm and 565nm, respectively.
The experimental results are shown in fig. 10, where FRET efficiency is highest when DiI: did=1:3 (mass ratio). Preparing DiI and DiD double fluorescent marks Lip in the ratio, preparing DiI and DiD double fluorescent marks ITP-Lip, PEG-Lip and PEG-ITP-Lip (DiI: diD=1:3 (mass ratio) fluorescein is properly weighed, dissolved in a mixed solution of methanol-chloroform (1:1, V: V) until the final concentration of total fluorescein is 1mg/mL, namely a fluorescein stock solution, weighing phospholipid 10mg, precisely weighing polypeptide and DSPE-PEG 2000 according to the ratio of EPC to DSPE-PEG 2000 (100:4:5), dissolving the polypeptide in proper ethanol, uniformly mixing lecithin solution and polypeptide solution, adding proper amount of fluorescein stock solution to ensure that the final concentration of the lecithin solution in liposome solution is 10 mug/mL, transferring the liposome stock solution into a round bottom distillation flask, removing an organic solvent by adopting a rotary evaporator, forming a lipid film at the bottom, introducing nitrogen residual organic solvent, immediately drying the solution into a constant temperature buffer solution of 1mL until the bottle bottom is dried, adding the constant temperature buffer solution into a PBS (100:4:5), shaking the bottle bottom until the liposome is completely dissolved in PBS, and performing the same shaking step of shaking to prepare the liposome, and fully dissolving the liposome in a blank. The prepared liposome and serum are mixed according to the proportion of (1:9, V:V), placed in a constant temperature oscillator, incubated at 37 ℃ and 120rpm, and each sample is taken at 0, 0.5, 1, 2, 4, 8, 12, 24 and 48 hours, and FRET fluorescence spectrum is scanned by a multifunctional enzyme-labeled instrument to calculate FRET efficiency.
Stability results as shown in fig. 11, the FRET efficiency of four groups of liposomes in serum decreased with time, but ITP-Lip and PEG-ITP-Lip groups modified with ITP were found to be significantly higher than Lip and PEG-Lip groups, indicating that ITP modification can increase serum stability of liposomes.
Example 9 investigation of targeting of ITP, AY, TF peptide-intercalating modified liposomes
The bEnd.3 cells in the logarithmic growth phase were digested and counted using a hemocytometer, seeded into 12-well plates at an seeding concentration of 2X 10 5 cells/well, and placed in a cell incubator for 24h (37 ℃,5% CO 2). Fresh complete medium was replaced by medium in wells, and prepared C6-labeled different polypeptides (ITP, AY, P0, P1, P2, P3, P4, P5 peptides) -modified liposomes (preparation method see example 4) were added to a final concentration of C6 of 1 μg/mL and incubated in an incubator protected from light for uptake for 2h. After the end of the uptake, the liposome-containing medium was aspirated, the cells were digested with trypsin for about 3min, pancreatin was discarded and washed three times with PBS, the cells were resuspended with PBS, centrifuged at 1000g for 5min, the supernatant was discarded and the pelleted cells were collected, 500. Mu.L of resuspended cells were added, and the cell uptake fluorescence intensity was measured using a flow cytometer.
As shown in FIG. 12, the fluorescence intensity of several polypeptide-embedded modified liposomes was significantly higher than that of PEG-Lip, demonstrating that the polypeptide-modified liposomes had active targeting to bEnd.3 cells.
And ITP, AY, TF polypeptides are selected for further in vivo targeting investigation. Lip, PEG-Lip (preparation method refers to example 8, and double fluorescent labels are changed into near infrared fluorescent probes DiR) and liposome modified by different polypeptides ITP, AY, TF (PEG-ITP-Lip, PEG-AY-Lip, PEG-TF-Lip; preparation method refers to example 6) for in vivo imaging of small animals. Wherein TF peptide group Balb/c mice adopts a right armpit mouse breast cancer TUBO subcutaneous tumor model, and ITP and AY peptide groups use healthy Balb/c mice.
DiR-labeled Lip, PEG-Lip, and different polypeptide (ITP, AY, TF) -modified liposome three-group formulations (100 μg DiR/kg) were injected into the tail vein, mice were anesthetized with isoflurane at 4h, and the in vivo fluorescence distribution of the mice was photographed and recorded using a VISQUE-animal fluorescence imaging system.
As shown in fig. 13, the brain fluorescence of the mice in the group of PEG-ITP-Lip and PEG-AY-Lip is stronger, which proves that the ITP and AY peptide embedded modified liposome has brain targeting; the PEG-TF-Lip group tumor tissue has stronger fluorescence, which indicates that the TF peptide embedded modified liposome shows tumor targeting. The results show that the three polypeptide guiding molecules embedded liposomes taking the membrane protein transmembrane region as the target have good in vivo targeting function.
EXAMPLE 10 immunogenicity investigation of AY peptide-embedded modified liposomes
Whole blood was collected from healthy Balb/c mice and serum was centrifuged. mu.L of liposomes (PEG-Lip, AY-Lip, PEG-AY-Lip, RGD-PEG-Lip) were mixed with an equal volume of serum and incubated for 1h at 37 ℃. The pellet was collected and washed twice with PBS and centrifuged at 14000g for 40min. The collected pellet was resuspended in 60. Mu.L PBS and 15. Mu.L 5 XSDS-PAGE sample buffer, and the mixture was boiled for 10min to denature the protein. Proteins were separated by SDS-PAGE and stained with a rapid silver staining kit. The preparation methods of AY-Lip, PEG-AY-Lip and RGD-PEG-Lip were the same as in example 6. The preparation method of the PEG-Lip comprises the following steps: 10mg of phospholipid was weighed according to EPC: DSPE-PEG 2000 (100:5, molar ratio) was precisely weighed DSPE-PEG 2000, dissolved in methanol-chloroform (1:1, V: V) mixed solution, transferred to a round bottom distillation flask, the organic solvent was removed by rotary evaporator, and after lipid film was formed at the bottom of the flask, nitrogen was introduced to blow dry the residual organic solvent. Immediately adding 1mL of PBS buffer solution into a round bottom flask, putting into a constant temperature oscillator for shaking until the lipid membrane is fully dissolved and dispersed, and carrying out the following steps in the same way as in the preparation of blank liposome in the example 3.
As shown in fig. 14, three groups of liposome modified by polypeptide (AY-Lip, PEG-AY-Lip, RGD-PEG-Lip) all have more remarkable IgM (72 kDa) adsorption than PEG-Lip, wherein RGD cyclic peptide modification results in the highest IgM adsorption level, and embedded modification of AY peptide can reduce IgM adsorption to some extent.
EXAMPLE 11ITP peptide-embedded modified Liposome intestinal stability investigation
The stability of the polypeptide targeting molecule embedded liposome small intestine is characterized by adopting a Fluorescence Resonance Energy Transfer (FRET) experiment. Proper amounts of fluorescein DiI and DiD are taken, precisely weighed, dissolved in ethanol and diluted to a final concentration of 1 mug/mL of stock solution for later use. The film hydration method is adopted to prepare different liposome (Lip, ITP-Lip, PEG-ITP-Lip) with fluorescein DiI and DiD double fluorescence marks, wherein the final concentration of the fluorescein DiI and DiD in the prepared liposome is 10 mug/mL and 30 mug/mL respectively.
Healthy Balb/c mice were taken in 12 groups of three randomly. The mice were given an appropriate amount of 1.4% sodium bicarbonate solution to neutralize the gastric acid by gavage, and after 0.5h, each group of liposomes (100 μg DiI/kg) was gavaged. Mice were sacrificed at 2h with excess isoflurane anesthesia, the duodenum, jejunum, ileum were carefully dissected out, tissue was embedded with OCT embedding medium and frozen sections were performed and samples transferred to adhesive slides. The slide was placed in a wet box, 4% paraformaldehyde fixing solution was added dropwise to the sample, and the mixture was fixed at room temperature for 30min. After the fixation is finished, the fixation liquid is discarded, PBS is used for soaking and washing for 3 times, and a high content imaging system is used for fluorescent imaging shooting.
The FRET imaging result of the polypeptide guide molecule embedded liposome in the small intestine section is shown in figure 15, and the FRET DiD fluorescence signal intensity of ITP-Lip and PEG-ITP-Lip groups modified by ITP is obviously higher than that of Lip and PEG-Lip groups, which indicates that the stability of the liposome in the small intestine can be obviously improved by ITP modification.
Finally, it is noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications and equivalents may be made thereto without departing from the spirit and scope of the present invention, which is intended to be covered by the claims of the present invention.
Claims (10)
1. The polypeptide targeting molecule embedded lipid complex is characterized in that the polypeptide targeting molecule can be embedded in a phospholipid bilayer of a lipid carrier and specifically identify a membrane protein transmembrane region, and the lipid complex is obtained by embedding the polypeptide targeting molecule into the lipid carrier.
2. The polypeptide targeting molecule embedded lipid complex according to claim 1, wherein the polypeptide targeting molecule comprises:
polypeptide directed against the insulin receptor transmembrane region: ELGILIFLYLFSLILGIIYWKK, ITP peptides;
polypeptide directed against the insulin receptor transmembrane region: LFGILIFLFLFSLIIGSIYLWKKK, P5 peptide;
Polypeptide directed against the integrin receptor transmembrane region: AYVFILLSFILGTLLGFLVMFWAKK, P4 peptide;
polypeptide directed against the integrin receptor transmembrane region: AYVFILLSFILGTLLGFLVMFWA, P0 peptide;
polypeptide directed against the integrin receptor transmembrane region: FILLSFILGTLLGFL, P1 peptide;
polypeptide directed against the integrin receptor transmembrane region: FILLSFILGT, P2 peptide;
Polypeptide directed against the integrin receptor transmembrane region: PEEFILKSFILGTLKGFLKMFYS, P3 peptide;
polypeptide directed against the integrin receptor transmembrane region: DDEFILLSFILGTLKGFLKMFWS, AY peptides;
polypeptide directed against the epidermal growth factor receptor-2 transmembrane region: TFIIATVEGVLLFLILVVVVGILIKRR, TF peptides.
3. The polypeptide targeting molecule embedded lipid complex according to claim 1, wherein the lipid carrier comprises a liposome, an exosome, a lipid nanoparticle.
4. The polypeptide targeting molecule intercalating lipid complex according to claim 1, wherein the lipid complex further comprises a modifying molecule, PEG.
5. The method for preparing a polypeptide-targeted molecule-embedded lipid complex according to claim 1, wherein when the lipid carrier is lecithin, the method for preparing the polypeptide-targeted molecule-embedded lipid complex is a thin film hydration method.
6. The method of claim 5, wherein the step of preparing the polypeptide targeting molecule comprises the steps of: the lecithin is 0.25-4% of the mole ratio, the raw materials are taken, precisely weighed, the raw materials are respectively dissolved by using an organic solvent, the organic solvent is removed after uniform mixing, the residual organic solvent is dried after forming a lipid film, PBS buffer solution is immediately added, the mixture is vibrated until the lipid film is fully dissolved and dispersed, and the particle size is controlled by ultrasonic and pushing and filtering, thus obtaining the lecithin.
7. The method for preparing a polypeptide targeting molecule embedded lipid complex as claimed in claim 1, wherein when the lipid carrier is exosome, the preparation method is as follows:
Collecting RAW 264.7 cell supernatant, centrifuging to remove cells and fragments, centrifuging the obtained supernatant at 135,000g for 1h, and washing the precipitate with PBS to obtain exosomes; dissolving the polypeptide targeting molecule in an organic solvent, and incubating with exosomes; unbound polypeptide-directed molecules are removed by ultracentrifugation.
8. The method for preparing a polypeptide targeting molecule intercalating lipid complex according to claim 1, characterized in that when the lipid carrier is a lipid nanoparticle, the preparation method is as follows: respectively dissolving an ionizable lipid ingredient, DSPC, a steroid compound, DMG-PEG 2000 and a polypeptide targeting molecule in an organic solvent and mixing in a molar ratio of 50:10:34.5:1.5:4; taking DEPC water as a water phase, and mixing the water phase and the organic solution according to the volume ratio of 3:1 at the mixing rate of 12 mL/min; dialyzing overnight with dialysis bag with molecular weight of 8-14K.
9. The method of claim 8, wherein the ionizable lipid moiety is Dlin-MC3-DMA or 2- (di ((9 e,12 e) -octadeca-9, 12-dien-1-yl) amino) ethyl (4 1 R,13 aS) -13 a-ethyl-2, 3,4 1, 5,6,13 a-hexahydro-1H-indolo [3,2,1-de ] pyrido [3,2,1-ij ] [1,5] naphthyridine-12-carboxylate, and the 2- (di ((9 e,12 e) -octadeca-9, 12-dien-1-yl) amino) ethyl (4 1 R,13 aS) -13 a-ethyl-2, 3,4 1, 5,6,13 a-hexahydro-1H-indolo [3,2,1-de ] pyrido [3,2,1-ij ] [1,5] naphthyridine-12-carboxylate has the formula:
the steroid compound is cholesterol or ginsenoside.
10. Use of a polypeptide targeting molecule embedded lipid complex according to claim 1 for the preparation of a targeted drug delivery system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410254290.6A CN118121547A (en) | 2024-03-06 | 2024-03-06 | Polypeptide guide molecule embedded lipid complex and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410254290.6A CN118121547A (en) | 2024-03-06 | 2024-03-06 | Polypeptide guide molecule embedded lipid complex and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118121547A true CN118121547A (en) | 2024-06-04 |
Family
ID=91229819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410254290.6A Pending CN118121547A (en) | 2024-03-06 | 2024-03-06 | Polypeptide guide molecule embedded lipid complex and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118121547A (en) |
-
2024
- 2024-03-06 CN CN202410254290.6A patent/CN118121547A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112957478B (en) | Method for surface modification of targeting ligand of Extracellular Vesicles (EVs) | |
| CN104558117B (en) | A kind of D configurations polypeptide of acetylcholine receptor mediated targeting and its application | |
| CN106619515A (en) | Liposomal compositions and uses of same | |
| CN107029239B (en) | Multifunctional targeting molecule and application thereof | |
| CN108309938B (en) | Drug delivery carrier for active customization of albumin crown and application of drug delivery carrier in pharmacy | |
| US20210252168A1 (en) | Amyloid b short peptide mediated brain targeted delivery system, preparation method therefor and use thereof | |
| CN108578711A (en) | A kind of acetylation sugar ester-mPEG2000-DSPE conjugate and the preparation method and application thereof | |
| CN110974971A (en) | Method for anchoring and modifying nano-drug on surface of living cell | |
| CN107550864B (en) | EPPT polypeptide-polyethylene glycol-phospholipid composite membrane material, preparation method thereof, active targeting liposome drug delivery system and application | |
| CN109432049B (en) | Rhein lipid vesicle nanoparticles with kidney targeting distribution characteristic and application thereof | |
| CN112898579B (en) | High polymer material, mixed micelle, preparation method and application thereof | |
| CN109422801B (en) | Multifunctional targeted polypeptide RAP and application thereof in preparation of tumor targeted delivery system | |
| CN108653743A (en) | Double target liposomes of a kind of heart and brain and its preparation method and application | |
| CN111249234B (en) | Preparation method and application of glycosyl-cell penetrating peptide-modified brain-targeted nanoliposome | |
| WO2016192149A1 (en) | Bis-alkoxyl amide alkyl cationic peptide lipids, synthesis method thereof, and application thereof | |
| CN110075300B (en) | Preparation method of targeted photothermal therapy and immunotherapy combined anti-tumor composite preparation | |
| CN110256585B (en) | M cell targeting and pH responsive starch-based carrier material and preparation method and application thereof | |
| CN118121547A (en) | Polypeptide guide molecule embedded lipid complex and preparation method and application thereof | |
| CN110840844A (en) | Preparation and application of biotin and glucose co-modified breast cancer targeted liposome | |
| CN110917139A (en) | Preparation and application of multi-branch biotin modified breast cancer targeted liposome | |
| CN113546179B (en) | Doxorubicin long circulation liposome targeting medicine and its preparation method | |
| CN110669101B (en) | D8 polypeptide specifically targeting acetylcholine receptor and having transmembrane effect and brain-targeted drug delivery system thereof | |
| CN110251686B (en) | Starch-based amphiphilic self-assembly carrier material and preparation method and application thereof | |
| CN106474492B (en) | Construction and application of adenosine 5' -monophosphate-mediated tumor-targeted nano delivery system | |
| CN115137836A (en) | Double-targeting ischemic myocardial mitochondria system based on carbon quantum dots and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |